Overview

Clinical Study of G Protein Biased - Opioid Receptor Agonist Oliceridine for Optimizing Postoperative Analgesia Under General Anesthesia

Status:
NOT_YET_RECRUITING

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

Traditional opioid analgesia is a treatment method for moderate to severe pain. However, the use of opioid drugs is not without risks. When treating acute pain, patients may experience hypotension, respiratory depression, hypoxia, nausea and vomiting, irritability, and itching. The purpose of this study is to evaluate the comparison of G protein biased - opioid receptor agonist oliceridine and traditional - opioid receptor agonist sufentanil in terms of analgesia in patients under general anesthesia.

Phase:

Details

Lead Sponsor:

Henan Provincial People's Hospital

Treatments:

((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine
Sufentanil